AGT’s progress over the first half of 2018 has been tremendous: six patents granted, major advances in all of its key projects: HIV, PKU and immuno-oncology, substantial momentum on social media with constant activity and announcements to thousands of followers, and huge growth in business development activities through outreach, events, and tradeshows. 2018 began with the annual JP Morgan Healthcare…

AGT is in position for key milestones and success in 2018. 2017 brought attention to the industry and particularly to AGT. We raised nearly $8M (approximately double the previous year), and efficiently leveraged the capital to advance AGT’s key technologies and pre-clinical programs. Our recent work has yielded critical data and materials to move forward…

American Gene Technologies International CEO, Jeff Galvin, is increasingly in demand for his thought leadership in addition to his vision for AGT. Jeff was invited to deliver the closing presentation at the June 13th HIMSS Precision Medicine Summit in Boston. He was also invited to join the morning leadership panel to discuss Ethical Issues, Access…

C. Neil Lyons AGT is announcing the appointment of C. Neil Lyons as Executive Vice President and Chief Financial Officer. Neil brings more than 30 years of experience in finance, strategy, capital, SEC compliance, and corporate governance in both public and private companies, and spent the most recent 10 years of that experience leading finance…

AGT and GeoVax Labs Inc. (OTCQB: GOVX) have announced a collaboration in preparation for a phase 1 clinical trial to test AGT’s HIV cure. This is the first announcement of several collaborations that will support testing the safety and feasibility of genetically modified CD4+T cells using our proprietary lentiviral vector technology. This lead therapeutic target…

We’ve kicked off 2017 with new intensity and excitement! AGT will be submitting our first Investigational New Drug (IND) application consistent with FDA’s great reception and feedback on our pre-IND application in November. We are on course to become a clinical stage biotech company in the 4th quarter of 2017. AGT”s executive team has attended…